Purple Book reference family · 351(a) biologic
Zoster Vaccine Recombinant, Adjuvanted (Shingrix)
Zoster Vaccine Recombinant, Adjuvanted is an FDA-licensed reference biologic from GlaxoSmithKline Biologicals.
351(a) biologicBLA 125614 GlaxoSmithKline Biologicals
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2017
Reference product
Originator biologic
351(a)BLA 125614
Shingrix Zoster Vaccine Recombinant, Adjuvanted
GlaxoSmithKline Biologicals
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Zoster Vaccine Recombinant, Adjuvanted product.
8 yr 11 mo ago
Zoster Vaccine Recombinant, Adjuvanted: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Zoster Vaccine Recombinant, Adjuvanted.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
